mepolizumab Injection

Brand(s)
Nucala
Category(s)
prescription
SPL Type(s)
Human Prescription
Master SPL
Glaxosmithkline Llc (2015-11-04)
Oldest Current Product
2015-11-04
License(s)
BLA
RxNORM
INJECTION\MEPOLIZUMAB
SPL Active
SUBCUTANEOUS\INJECTION, POWDER, FOR SOLUTION\MEPOLIZUMAB
SPL Moiety
SUBCUTANEOUS\INJECTION, POWDER, FOR SOLUTION\MEPOLIZUMAB

product(s) by strength(s)

mepolizumab 100 mg injection

product(s)(s)

#idbrandcategorylabelerfirst marketedactive ingredient(s)routedose formapplicationspl
1001730881NucalaBLAGlaxosmithkline Llc2015-11-04MEPOLIZUMABSUBCUTANEOUSINJECTION, POWDER, FOR SOLUTION125526fefb887c-e4ac-431e-8893-e9d1a5a63fea

spl(s)

#idtitlecategorytypelabelerlast updateversionproduct(s)
1fefb887c-e4ac-431e-8893-e9d1a5a63fea (view SPL)These highlights do not include all the information needed to use NUCALA safely and effectively. See full prescribing information for NUCALA. NUCALA (mepolizumab) for injection, for subcutaneous useInitial U.S. Approval: 2015prescriptionHuman PrescriptionGlaxosmithkline Llc2015-11-042001730881

Data from: LOINC, MTHSPL, NDFRT, NCIT, RxNORM, UNII